Rapiscan is administered as a non-weight based bolus injection and is the first and only selective A2A adenosine receptor agonist to have a licence for use in this indication.
Rapiscan simulates the effects of exercise by temporarily increasing blood flow through the arteries of the heart, providing an option for such patients.
Rapiscan requires no dose adjustment for varying body weight and its bolus dosing method is rapid (taking just 10 seconds), cutting out the need for an infusion pump and its set-up.
Rapidscan Pharma Solutions founder, president and CEO Brent Blackburn said Rapiscan was designed to address the needs of patients and healthcare professionals who conduct MPI tests and its easier to use and better tolerated than the older agents.